BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 20182726)

  • 1. "Metronomic" chemotherapy in advanced soft tissue sarcomas.
    Italiano A; Toulmonde M; Lortal B; Stoeckle E; Garbay D; Kantor G; Kind M; Coindre JM; Bui B
    Cancer Chemother Pharmacol; 2010 May; 66(1):197-202. PubMed ID: 20182726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study.
    Lorigan P; Verweij J; Papai Z; Rodenhuis S; Le Cesne A; Leahy MG; Radford JA; Van Glabbeke MM; Kirkpatrick A; Hogendoorn PC; Blay JY;
    J Clin Oncol; 2007 Jul; 25(21):3144-50. PubMed ID: 17634494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of 9-nitro-camptothecin in patients with advanced chordoma or soft tissue sarcoma.
    Chugh R; Dunn R; Zalupski MM; Biermann JS; Sondak VK; Mace JR; Leu KM; Chandler WF; Baker LH
    J Clin Oncol; 2005 May; 23(15):3597-604. PubMed ID: 15908670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liposomal doxorubicin (Caelyx) in advanced pretreated soft tissue sarcomas: a phase II study of the Italian Sarcoma Group (ISG).
    Toma S; Tucci A; Villani G; Carteni G; Spadini N; Palumbo R
    Anticancer Res; 2000; 20(1B):485-91. PubMed ID: 10769710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bendamustine hydrochloride in patients with refractory soft tissue sarcoma: a noncomparative multicenter phase 2 study of the German sarcoma group (AIO-001).
    Hartmann JT; Mayer F; Schleicher J; Horger M; Huober J; Meisinger I; Pintoffl J; Käfer G; Kanz L; Grünwald V;
    Cancer; 2007 Aug; 110(4):861-6. PubMed ID: 17599772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose ifosfamide with hematopoietic growth factor support in advanced bone and soft tissue sarcomas.
    Yalcin B; Pamir A; Buyukcelik A; Utkan G; Akbulut H; Demirkazik A; Icli F
    Exp Oncol; 2004 Dec; 26(4):320-5. PubMed ID: 15627067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy of a combination of etoposide, ifosfamide, and cisplatin in the treatment of patients with soft tissue sarcoma.
    Pápai Z; Bodoky G; Szántó J; Poller I; Rahóty P; Eckhardt S; Láng I; Szendroi M
    Cancer; 2000 Jul; 89(1):177-80. PubMed ID: 10897015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exatecan in pretreated adult patients with advanced soft tissue sarcoma: results of a phase II--study of the EORTC Soft Tissue and Bone Sarcoma Group.
    Reichardt P; Nielsen OS; Bauer S; Hartmann JT; Schöffski P; Christensen TB; Pink D; Daugaard S; Marreaud S; Van Glabbeke M; Blay JY;
    Eur J Cancer; 2007 Apr; 43(6):1017-22. PubMed ID: 17336054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of epothilone B analog in advanced soft tissue sarcoma: a phase II study of the phase II consortium.
    Okuno S; Maples WJ; Mahoney MR; Fitch T; Stewart J; Fracasso PM; Kraut M; Ettinger DS; Dawkins F; Erlichman C
    J Clin Oncol; 2005 May; 23(13):3069-73. PubMed ID: 15860865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial growth factor receptor levels as markers of response.
    Wong NS; Buckman RA; Clemons M; Verma S; Dent S; Trudeau ME; Roche K; Ebos J; Kerbel R; Deboer GE; Sutherland DJ; Emmenegger U; Slingerland J; Gardner S; Pritchard KI
    J Clin Oncol; 2010 Feb; 28(5):723-30. PubMed ID: 20026801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequential dose-dense doxorubicin and ifosfamide for advanced soft tissue sarcomas: a Phase II trial by the Spanish Group for Research on Sarcomas (GEIS).
    Maurel J; Fra J; López-Pousa A; García del Muro X; Balañá C; Casado A; Martín J; Martínez-Trufero J; de las Peñas R; Buesa JM;
    Cancer; 2004 Apr; 100(7):1498-506. PubMed ID: 15042685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A threefold dose intensity treatment with ifosfamide, carboplatin, and etoposide for patients with small cell lung cancer: a randomized trial.
    Leyvraz S; Pampallona S; Martinelli G; Ploner F; Perey L; Aversa S; Peters S; Brunsvig P; Montes A; Lange A; Yilmaz U; Rosti G;
    J Natl Cancer Inst; 2008 Apr; 100(8):533-41. PubMed ID: 18398095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of daily oral perifosine in patients with advanced soft tissue sarcoma.
    Bailey HH; Mahoney MR; Ettinger DS; Maples WJ; Fracasso PM; Traynor AM; Erlichman C; Okuno SH
    Cancer; 2006 Nov; 107(10):2462-7. PubMed ID: 17058289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Salvage chemotherapy for recurrent spinal cord ependymona.
    Chamberlain MC
    Cancer; 2002 Sep; 95(5):997-1002. PubMed ID: 12209682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ifosfamide, carboplatin, etoposide, and paclitaxel chemotherapy: a dose-escalation study.
    Chang AY; Boros L; Garrow GC; Asbury RF; Hui L
    Semin Oncol; 1996 Jun; 23(3 Suppl 6):74-7. PubMed ID: 8677454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of intravenous TZT-1027 in patients with advanced or metastatic soft-tissue sarcomas with prior exposure to anthracycline-based chemotherapy.
    Patel S; Keohan ML; Saif MW; Rushing D; Baez L; Feit K; DeJager R; Anderson S
    Cancer; 2006 Dec; 107(12):2881-7. PubMed ID: 17109446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Second-line chemotherapy with biweekly paclitaxel after failure of fluoropyrimidine-based treatment in patients with advanced or recurrent gastric cancer: a report from the gastrointestinal oncology group of the Tokyo cooperative oncology group, TCOG GC-0501 trial.
    Koizumi W; Akiya T; Sato A; Yamaguchi K; Sakuyama T; Nakayama N; Tanabe S; Higuchi K; Sasaki T; Sekikawa T;
    Jpn J Clin Oncol; 2009 Nov; 39(11):713-9. PubMed ID: 19812061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study.
    Penel N; Bui BN; Bay JO; Cupissol D; Ray-Coquard I; Piperno-Neumann S; Kerbrat P; Fournier C; Taieb S; Jimenez M; Isambert N; Peyrade F; Chevreau C; Bompas E; Brain EG; Blay JY
    J Clin Oncol; 2008 Nov; 26(32):5269-74. PubMed ID: 18809609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of neoadjuvant vincristine, ifosfamide, and doxorubicin with granulocyte colony-stimulating factor support in children and adolescents with advanced-stage nonrhabdomyosarcomatous soft tissue sarcomas: a Pediatric Oncology Group Study.
    Pappo AS; Devidas M; Jenkins J; Rao B; Marcus R; Thomas P; Gebhardt M; Pratt C; Grier HE
    J Clin Oncol; 2005 Jun; 23(18):4031-8. PubMed ID: 15767644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.